HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.109.063602v1 50/9/1435    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Cheon, G. J. Articles by Jeon, D.-G. PubMed PubMed Citation Articles by Cheon, G. J. Articles by Jeon, D.-G.

Prediction Model of Chemotherapy Response in Osteosarcoma by ¹⁸F-FDG PET and MRI

¹ Department of Nuclear Medicine, Korea Cancer Center Hospital, Seoul, Korea; ² Department of Molecular Imaging Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea; ³ Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea; ⁴ Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea; ⁵ Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea; ⁶ Department of Radiology, Korea Cancer Center Hospital, Seoul, Korea; and ⁷ Department of Orthopedic Surgery, Yeungnam University College of Medicine, Daegu, Korea

Correspondence: For correspondence or reprints contact: Dae-Geun Jeon, Department of Orthopedic Surgery, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Korea. E-mail: dgjeon{at}kcch.re.kr.

Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma; however, this information can be determined only after surgical resection. If we could predict histologic response before surgery, it might be helpful for the planning of surgeries and tailoring of treatment. We evaluated the usefulness of ¹⁸F-FDG PET for this purpose. Methods: A total of 70 consecutive patients with a high-grade osteosarcoma treated at our institute were prospectively enrolled. All patients underwent ¹⁸F-FDG PET and MRI before and after neoadjuvant chemotherapy. We analyzed the predictive values of 5 parameters, namely, maximum standardized uptake values (SUVs), before and after (SUV2) chemotherapy, SUV change ratio, tumor volume change ratio, and metabolic volume change ratio (MVCR) in terms of their abilities to discriminate responders from nonresponders. Results: Patients with an SUV2 of less than or equal to 2 showed a good histologic response, and patients with an SUV2 of greater than 5 showed a poor histologic response. The histologic response of a patient with an intermediate SUV2 (2 < SUV2 5) was found to be predictable using MVCR. A patient with an MVCR of less than 0.65 is likely to be a good responder, whereas a patient with an MVCR of greater than or equal to 0.65 is likely to be a poor responder. According to our model, the predictive values for good responders and poor responders were 97% (31/32) and 95% (36/38), respectively. Conclusion: We found that combined information on ¹⁸F-FDG PET and MRI scans, acquired before and after chemotherapy, could be used to predict histologic response to neoadjuvant chemotherapy in osteosarcoma.

Key Words: correlative imaging • oncology • PET • ¹⁸F-FDG PET • MRI • chemotherapy response • osteosarcoma

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]